Research Study

An Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis
Principal Investigator 
Robert Carruthers

Overview

Body Locations and Systems 
Multiple Sclerosis
ClinicalTrials.gov# 
nct03085810
Status 
Recruiting
Study Start/End 
Jul 25, 2017 to Nov 1, 2022
Locations 
UBC Hospital
Name/Title 
study coordinator
Phone 
604-822-1756
Email Address 
MS.NMO_Research@ubc.ca
Purpose of Study 

This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS. The study will consist of an open-label treatment period of 192 weeks and follow-up period of at least 48 weeks.

Eligibility 

See Clinicaltrials.gov

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.